Publication | Closed Access
Responses to USPSTF Guideline on Aspirin for Prevention of Cardiovascular Disease
10
Citations
1
References
2009
Year
HypertensionCardiovascular PharmacologyPopulation Health SciencesPharmacotherapyPreventive CardiologyThrombosisPreventive MedicineClinical EpidemiologyClinical TrialsPublic HealthPlatelet AntagonistAtherosclerosisPercutaneous Coronary InterventionPrimary PreventionCardiovascular EpidemiologyHealth PolicyAntihypertensive TherapyBiobehavioral HealthPharmacologyEpidemiologyCardiovascular DiseaseUspstf GuidelineMedicineAnticoagulantWomen's Health
Letters20 October 2009Responses to USPSTF Guideline on Aspirin for Prevention of Cardiovascular DiseaseNed Calonge, MD, MPH, Diana Petitti, MD, MPH, and Mary Barton, MD, MPPNed Calonge, MD, MPHFrom U.S. Preventive Services Task Force, Rockville, MD 20850., Diana Petitti, MD, MPHFrom U.S. Preventive Services Task Force, Rockville, MD 20850., and Mary Barton, MD, MPPFrom U.S. Preventive Services Task Force, Rockville, MD 20850.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-8-200910200-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the thoughtful letters from Dr. Budhraja and Dr. Mohan and colleagues regarding the USPSTF recommendation on aspirin prophylaxis for the prevention of cardiovascular disease. Dr. Budhraja calls attention to subgroups of women in whom the effect of aspirin in preventing cardiovascular disease may differ from that of the general population. In general, the USPSTF is cautious when considering unplanned subgroup analyses of randomized trials, which are the basis for Dr. Budhraja's comment. The authors of the original report from the Women's Health Study (1) mention multiple comparisons as an additional caution in interpreting this subgroup analysis. ...Reference1. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304. [PMID: 15753114] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From U.S. Preventive Services Task Force, Rockville, MD 20850.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation StatementResponses to USPSTF Guideline on Aspirin for Prevention of Cardiovascular Disease Vikram Budhraja Responses to USPSTF Guideline on Aspirin for Prevention of Cardiovascular Disease Arun V. Mohan , Carmen Patrick Mohan , and Richard Balaban Metrics Cited ByProgram Directors' Perceptions of Resident Education in Women's Health: A National SurveyCost-Effectiveness of Tomosynthesis in Annual Screening MammographyMammographic features associated with interval breast cancers in screening programsApplications of Personalized Estimates of Absolute Breast Cancer RiskDo physician communication skills influence screening mammography utilization?Screening Mammography, Patient Decision-Making, and Absolute RisksResponse to Hendrick and Helvie by the Cancer Intervention Surveillance Modeling Network (CISNET) Breast Working GroupDiscordance of Individual Risk Estimates 20 October 2009Volume 151, Issue 8Page: 588KeywordsCardiovascular disease riskCardiovascular diseasesCohort studiesObstetrics and gynecologyPeptic ulcersPrecision medicineProphylaxisResearch quality assessment ePublished: 20 October 2009 Issue Published: 20 October 2009 CopyrightCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
| Year | Citations | |
|---|---|---|
Page 1
Page 1